Showing results (111-120 of 126) with videos related to
Sort By:
Pageof 13
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 29, 2005
Clinical variables associated with early administration of antipsychotics in bipolar maniaChi-Un Pae, Tae-Suk Kim, Kyong-Uk Lee, et al.Journal of Clinical Psychopharmacology|August 13, 2015
Antidepressants in Type II Versus Type I Bipolar Depression: A Randomized Discontinuation TrialPaul A Vöhringer, Michael J Ostacher, Rif S El-Mallakh, et al.Plos One|May 1, 2012
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed stateAshwin Patkar, William Gilmer, Chi-un Pae, et al.The British Journal of Psychiatry : the Journal of Mental Science|April 2, 2004
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneMauricio Tohen, K N Roy Chengappa, Trisha Suppes, et al.Clinical and Translational Science|October 11, 2023
MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose)Baltazar Gomez-Mancilla, Jeffrey A Levy, Subramanian Ganesan, et al.The Journal of Clinical Psychiatry|August 6, 2025
Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept StudyRichard C Shelton, Robert E Litman, Howard Hassman, et al.Journal of Affective Disorders|March 29, 2011
Sensitivity and specificity of the mood disorder questionnaire and the bipolar spectrum diagnostic scale in Argentinean patients with mood disordersRodolfo M Zaratiegui, Gustavo H Vázquez, Laura S Lorenzo, et al.Journal of Clinical Psychopharmacology|February 21, 2013
Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorderGabriele Sani, Georgios D Kotzalidis, Paul Vöhringer, et al.Bipolar Disorders|July 24, 2009
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disordersMauricio Tohen, Ellen Frank, Charles L Bowden, et al.Science (New York, N.Y.)|July 25, 2020
The activities of drug inactive ingredients on biological targetsJoshua Pottel, Duncan Armstrong, Ling Zou, et al.Pageof 13